Literature DB >> 10205166

A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'.

A D Watts1, N H Hunt, Y Wanigasekara, G Bloomfield, D Wallach, B D Roufogalis, G Chaudhri.   

Abstract

We have identified a putative signalling feature of the cytoplasmic domains of the tumour necrosis factor (TNF) family members based on available amino acid sequence data. A casein kinase I (CKI) consensus sequence is conserved in the cytoplasmic domain of six of 15 members of the type II integral membrane TNF ligand family. We examined the phosphorylation state of transmembrane tumour necrosis factor-alpha (mTNF) with [32P]orthophosphate labelling and in vitro kinase assays, in lipopolysaccharide-stimulated RAW264.7 cells. A dimeric form of the type I soluble TNF receptor (sTNFR) was found to dephosphorylate mTNF. This effect could be prevented by treatment with phosphatase inhibitors. Recombinant CKI was able to phosphorylate mTNF that had been dephosphorylated by sTNFR ligation in vivo, and this was less effective if phosphatase inhibitors had been used to prevent mTNF dephosphorylation. A mutated form of mTNF, lacking the CKI recognition site, cannot be phosphorylated by the enzyme. Binding of sTNFR to mTNF induced an increase in intracellular calcium levels in RAW264.7 cells, implying the presence of an associated signalling pathway. We predict that this CKI motif is phosphorylated in other TNF ligand members, and that it represents a new insight into the mechanism of 'reverse signalling' in this cytokine family.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205166      PMCID: PMC1171296          DOI: 10.1093/emboj/18.8.2119

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  50 in total

1.  4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells.

Authors:  K E Pollok; Y J Kim; J Hurtado; Z Zhou; K K Kim; B S Kwon
Journal:  Eur J Immunol       Date:  1994-02       Impact factor: 5.532

Review 2.  CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

Authors:  B Falini; S Pileri; G Pizzolo; H Dürkop; L Flenghi; F Stirpe; M F Martelli; H Stein
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

Review 3.  The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death.

Authors:  C A Smith; T Farrah; R G Goodwin
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

4.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases.

Authors:  A J Gearing; P Beckett; M Christodoulou; M Churchill; J Clements; A H Davidson; A H Drummond; W A Galloway; R Gilbert; J L Gordon
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

5.  Differential regulation of biosynthesis of cell surface and secreted TNF-alpha in LPS-stimulated murine macrophages.

Authors:  G Chaudhri
Journal:  J Leukoc Biol       Date:  1997-08       Impact factor: 4.962

6.  Circulating plasma receptors for tumour necrosis factor in Malawian children with severe falciparum malaria.

Authors:  M E Molyneux; H Engelmann; T E Taylor; J J Wirima; D Aderka; D Wallach; G E Grau
Journal:  Cytokine       Date:  1993-11       Impact factor: 3.861

7.  A lymphotoxin-beta-specific receptor.

Authors:  P D Crowe; T L VanArsdale; B N Walter; C F Ware; C Hession; B Ehrenfels; J L Browning; W S Din; R G Goodwin; C A Smith
Journal:  Science       Date:  1994-04-29       Impact factor: 47.728

8.  Infectious complications in 100 consecutive heart transplant recipients.

Authors:  M Waser; M Maggiorini; A Lüthy; A Laske; L von Segesser; P Mohacsi; M Opravil; M Turina; F Follath; A Gallino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

9.  Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.

Authors:  G M McGeehan; J D Becherer; R C Bast; C M Boyer; B Champion; K M Connolly; J G Conway; P Furdon; S Karp; S Kidao
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

10.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing.

Authors:  K M Mohler; P R Sleath; J N Fitzner; D P Cerretti; M Alderson; S S Kerwar; D S Torrance; C Otten-Evans; T Greenstreet; K Weerawarna
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

View more
  38 in total

1.  Fas ligand enhances malignant behavior of tumor cells through interaction with Met, hepatocyte growth factor receptor, in lipid rafts.

Authors:  Huan-Ching Lin; Po-Yin Lai; Yu-ping Lin; Jyun-Yuan Huang; Bei-Chang Yang
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 2.  Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system.

Authors:  Sara L Montgomery; William J Bowers
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

3.  Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis.

Authors:  M Vigna-Pérez; C Abud-Mendoza; H Portillo-Salazar; B Alvarado-Sánchez; E Cuevas-Orta; R Moreno-Valdés; L Baranda; O Paredes-Saharopulos; R González-Amaro
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 4.  The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies.

Authors:  David Wallach
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-10-01       Impact factor: 10.005

Review 5.  Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.

Authors:  Bharat B Aggarwal; Subash C Gupta; Ji Hye Kim
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

6.  Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells.

Authors:  Nalini K Vudattu; Ernst Holler; Patricia Ewing; Ute Schulz; Silvia Haffner; Verena Burger; Silvia Kirchner; Reinhard Andreesen; Günther Eissner
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

Review 7.  PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.

Authors:  C K Edwards
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 8.  Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).

Authors:  Pengfei Xu; Chiara Ianes; Fabian Gärtner; Congxing Liu; Timo Burster; Vasiliy Bakulev; Najma Rachidi; Uwe Knippschild; Joachim Bischof
Journal:  Gene       Date:  2019-07-31       Impact factor: 3.688

Review 9.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

Review 10.  Phosphorylation events and the modulation of aquaporin 2 cell surface expression.

Authors:  Dennis Brown; Udo Hasler; Paula Nunes; Richard Bouley; Hua A J Lu
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-09       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.